Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

41. Post-progression survival and immune-related adverse events of immune-checkpoint inhibitors in multiple types of malignancies: a systematic review and network meta-analysis

Post-progression survival and immune-related adverse events of immune-checkpoint inhibitors in multiple types of malignancies: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

42. Predictors of medication related adverse events in wards inpatients

Predictors of medication related adverse events in wards inpatients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

43. Exercise training for protecting against major adverse health events in people with dementia: a systematic review and individual patient data meta-analysis

Exercise training for protecting against major adverse health events in people with dementia: a systematic review and individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

44. Mixed methods review to explore the incidence, prevalence and experiences of women in LMICs who have experienced an adverse event or complications as a result of cervical cerclage to reduce the risk of PTB

Mixed methods review to explore the incidence, prevalence and experiences of women in LMICs who have experienced an adverse event or complications as a result of cervical cerclage to reduce the risk of PTB Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

45. Cutaneous adverse events of PD-1 and PD-L1 inhibitors

Cutaneous adverse events of PD-1 and PD-L1 inhibitors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

46. Correlation between immune-related adverse events occurrence and efficacy of immune checkpoint inhibitors in cancer patients

Correlation between immune-related adverse events occurrence and efficacy of immune checkpoint inhibitors in cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

47. Predictors of poor response and adverse events following botulinum toxin A for refractory idiopathic overactive bladder: a systematic review

Predictors of poor response and adverse events following botulinum toxin A for refractory idiopathic overactive bladder: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

48. Lymphocyte-to-monocyte ratio predicts mortality and major adverse cardiac and cerebrovascular events in coronary heart disease patients: a systematic review and meta-analysis

Lymphocyte-to-monocyte ratio predicts mortality and major adverse cardiac and cerebrovascular events in coronary heart disease patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

49. Prognostic performance of post-operative troponin in mortality and major adverse cardiac events after vascular surgery: systematic review and meta-analysis

Prognostic performance of post-operative troponin in mortality and major adverse cardiac events after vascular surgery: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

50. Risk management - instruments used for the investigation of adverse events: systematic review

Risk management - instruments used for the investigation of adverse events: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

51. Adverse events associated with treatment of tripterygium glycosides: a systematic review and meta-analysis

Adverse events associated with treatment of tripterygium glycosides: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

52. Adverse events following spinal cord injury: spectrum, relation to clinical outcome, prevention, and management methods

Adverse events following spinal cord injury: spectrum, relation to clinical outcome, prevention, and management methods Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

53. The quality of CONSORT adverse events reporting in phase III randomized controlled trials of breast and colorectal cancers: a systematic review

The quality of CONSORT adverse events reporting in phase III randomized controlled trials of breast and colorectal cancers: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

54. Perioperative and postoperative hypotension as a risk factor for postoperative cardiovascular major adverse events and mortality

Perioperative and postoperative hypotension as a risk factor for postoperative cardiovascular major adverse events and mortality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

55. Predicting major adverse cardiovascular events for secondary prevention: systematic review and meta-analysis of risk prediction models

Predicting major adverse cardiovascular events for secondary prevention: systematic review and meta-analysis of risk prediction models Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

56. Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography. (PubMed)

Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography. 29459959 2018 12 24 2018 12 24 1539-3704 168 4 2018 02 20 Annals of internal medicine Ann. Intern. Med. Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography. JC22 10.7326/ACPJC-2018-168-4-022 Carnicelli Anthony P AP Granger Christopher B CB eng Journal Article Comment United States Ann Intern Med 0372351 0003-4819 0

2018 Annals of Internal Medicine

57. [Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. (PubMed)

[Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. Antiphospholipid syndrome is defined by the presence of thrombosis and/or obstetrical adverse events (≥3 recurrent early miscarriage or fetal death or a prematurity<34 weeks of gestation) associated with persistent antiphospholipid antibodies. The pregnancy outcome has been improved by the conventional treatment (aspirin 100mg (...) /day with low molecular weight heparin [LMWH] from 30 to 75% of uncomplicated pregnancies. In PROMISSE study, 19% of pregnancies had at least one obstetrical adverse event despite treatment (maternal, fetal or neonatal complications) in relation with APS. In the European registry of babies born from APS mothers, maternal and foetal adverse events were observed in 13% of cases, with prematurity in 14% despite treatment. The presence of lupus erythematosus, a history of thrombosis, presence of lupus

2018 Gynecologie, obstetrique, fertilite & senologie

58. Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. (PubMed)

Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Epidemiological evidence has suggested a link between use of beta₂-agonists and increased asthma mortality. Much debate has surrounded possible causal links for this association, and whether regular (daily) long-acting beta₂-agonists (LABAs) are safe, particularly when used in combination with inhaled corticosteroids (ICSs). This is an update of a Cochrane Review that now includes data from two large trials (...) including 11,679 adults and 6208 children; both were mandated by the US Food and Drug Administration (FDA).  OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS.We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trials registers for unpublished trial data. We also checked FDA

2018 Cochrane

59. In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization

In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization Studies using hospital discharge data likely underestimate postoperative morbidity and mortality after lower extremity revascularization because they fail to capture postdischarge events. However, the degree of underestimation and the timing of postdischarge complications are not well-characterized.We used the American College of Surgeons National Surgical Quality Improvement Program (...) procedure-targeted vascular databases from 2011 to 2015 to tabulate 30-day adverse events (in hospital and after discharge) for lower extremity bypass (LEB) and percutaneous vascular interventions (PVIs) performed for claudication and chronic limb-threatening ischemia (CLTI).A total of 14,125 patients underwent lower extremity revascularization, 8909 patients (63%) with LEB and 5216 (37%) with PVI. For CLTI, total 30-day mortality was similar between PVI and LEB (2.3% vs 2.1%; P = .61), but in-hospital

2018 EvidenceUpdates

60. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. (PubMed)

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern.Register based cohort study.Sweden and Denmark from July 2013 to December 2016.A propensity score matched cohort of 17 213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin, 38%; canagliflozin, 1%) and 17 213 new users (...) of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Full Text available with Trip Pro

2018 BMJ